Newco Kyras emerges from Versant's Highline

Kyras Therapeutics Inc. (New York, N.Y.) raised $5 million in a series A round led by Versant Ventures. The cancer company is the first to emerge from Highline Therapeutics, an incubator that Versant announced this summer (see BioCentury, Aug. 24).

Kyras has an exclusive license from Columbia University to small molecule Ras inhibitors that non-covalently bind the target. ...